Bacigalupo et al
1 recently reported the favorable results of a pilot study in 18 patients considered at high risk for graftversus-host disease (GVHD), suggesting that pre-emptive therapy of GVHD with antithymocyte globulins (ATG) may decrease its incidence. There is further evidence in the literature to support that such an approach may be called for in some patients who are considered at high risk for GVHD. Patients with Fanconi's anemia (FA) who undergo matched related allogeneic stem cell transplantation (SCT) appear to be a particularly susceptible group to GVHD, both acute and chronic, probably because of the significant tissue damage that occurs during the procedure because of the underlying DNA repair defect.
We recently published our results in 19 patients with FA after SCT using low-dose cyclophosphamide (CY) 20 mg/ kg, thoracoabdominal irradiation (TAI) and Equine ATG at a dose of 40 mg/kg on days 6, 4, and 2 pretransplant. GVHD prophylaxis was with cyclosporine with or without Methotrexate, in addition to ATG 20 mg/kg on days 2, 4, 6, 8, 10, and 12 post-transplant. Only three patients developed grade II acute GVHD (16.6%) and no patient thus far developed chronic GVHD. 2 Our results confirm those published previously by Kholi-Kumar et al when they used the same conditioning regimen: low-dose CY/TAI/ATG; GVHD prophylaxis was with cyclosporine (CSA), prednisone and ATG. A total of 18 patients were transplanted, no acute GVHD was observed in any patient and a total of three patients developed chronic GVHD (16%). 3 Conversely, several groups reported a remarkably high incidence of GVHD in patients with FA who underwent SCT, but ATG was not part of their GVHD prophylaxis regimens. Flowers et al reported grades II-III acute GVHD in seven out of 17 patients with FA (41%) who were conditioned with CY 120-200 mg/kg with or without TBI. Extensive chronic GVHD developed in four of nine patients at risk (44%), GVHD prophylaxis was with cyclosporine with or without Methotrexate. 4 Similarly, Zanis-Neto et al reported the results of 22 patients with FA who underwent SCT after preparation with CY at doses ranging from 20 to 200 with TBI added to the patients who received the lower dose of CY. ATG was used in nine patients for three doses pre-SCT, GVHD prophylaxis was with cyclosporine with or without Methotrexate. Acute GVHD developed in nine patients (41%), one patient developed chronic GVHD. 5 Furthermore, the use of even lower doses of CY (20-40 mg/kg) plus TAI appears also to be associated with a high incidence of GVHD as was reported by Socie´et al when they updated their results on 50 patients with FA after SCT; GVHD prophylaxis consisted of cyclosporine alone. Grade II or more acute GVHD occurred in 26 patients at risk (55%) and chronic GVHD developed in 30 patients at risk (69.9%). 6 Thus, the incidence of GVHD appears significantly lower in trials that employed ATG post SCT for patients with FA suggesting that there may be a role for ATG to help decrease the incidence of GVHD in certain selected highrisk patients. A major concern associated with the use of ATG remains, however, the development of secondary malignancies, especially EBV-related lymphomas.
